Zika virus (ZIKV) has recently emerged as a global health concern owing to its widespread diffusion and its association with severe neurological symptoms and microcephaly in newborns 1 . However, the molecular mechanisms that are responsible for the pathogenicity of ZIKV remain largely unknown. Here we use human neural progenitor cells and the neuronal cell line SK-N-BE2 in an integrated proteomics approach to characterize the cellular responses to viral infection at the proteome and phosphoproteome level, and use affinity proteomics to identify cellular targets of ZIKV proteins. Using this approach, we identify 386 ZIKV-interacting proteins, ZIKV-specific and pan-flaviviral activities as well as host factors with known functions in neuronal development, retinal defects and infertility. Moreover, our analysis identified 1,216 phosphorylation sites that are specifically up-or downregulated after ZIKV infection, indicating profound modulation of fundamental signalling pathways such as AKT, MAPK-ERK and ATM-ATR and thereby providing mechanistic insights into the proliferation arrest elicited by ZIKV infection. Functionally, our integrative study identifies ZIKV host-dependency factors and provides a comprehensive framework for a system-level understanding of ZIKV-induced perturbations at the levels of proteins and cellular pathways.
. To comprehensively understand how ZIKV affects neuronal cells, we performed an unbiased proteomic survey to identify cellular proteins and associated complexes that interact with each of the ten ZIKV proteins expressed in human SK-N-BE2 neuroblastoma cells (Extended Data Fig. 1a) . Except for NS2A, all ZIKV proteins were correctly expressed and processed (Extended Data Fig. 1b, c) . Affinity purification coupled with liquid chromatography and tandem mass spectrometry (AP-LC-MS/MS), followed by Bayesian statistical modelling, identified 386 proteins specifically associating with ZIKV proteins, resulting in 484 high-confident interactions ( Table 1) . We identified previously reported proteins that showed bona fide interactions with flavivirus proteins, including subunits of the ATPase (ATP1A1, ATP1A2, ATP1A3, ATP1B and ATP6V1H), voltage-dependent anion-selective channel proteins (VDAC1, VDAC2 and VDAC3) as well as components of the cytochrome c oxidase complex (COX15, MT-CO2 and NDUFA4), confirming these processes as important targets of diverse flaviviruses 3 ( Fig. 1 and Extended Data Fig. 2 ). Notably, this analysis uncovered proteins linked to neurological diseases or development, particularly among the proteins that specifically interacted with capsid and NS4B (Fig. 1 ). For instance, the capsidinteracting proteins included LARP7 (involved in telomere stability and mutated in Alazami syndrome) 4 , LYAR (important for maintenance of embryonic stem cell identity) 5 and NGDN (a neuronal development factor) 6 (Extended Data Fig. 3a ). NS4B has recently been implicated in the inhibition of neuronal development 7 . Compared to HCV-NS4B, ZIKV-NS4B showed specific enrichment in cellular proteins associated with the whole spectrum of ZIKV-associated pathogenesis, ranging from neurodegenerative disorders and retinal degeneration (CLN6 and BSG) 8, 9 to regulators of neuronal differentiation (CEND1 and RBFOX2) 10, 11 and axonal dysfunction (CHP1 and TMEM41b) 12 ( Fig. 1 and Extended Data Figs. 2-4a). Co-immunoprecipitation followed by western blotting of transduced or ZIKV-infected cells verified that these proteins specifically associate with arthropod-borne NS4Bs (such as those of dengue virus and ZIKV) and not NS4B of other Flaviviridae, such as HCV; with a subset of proteins specifically binding to ZIKV-NS4B only (TMEM41b, CEND1 and CLN6; Extended Data Fig. 4b, c) . ZIKV-NS4B precipitated particularly well with ceroid-lipofuscinosis neuronal protein 6 (CLN6), which is associated with a lysosomal storage disease that causes neurodegenerative late-infantile disorders as well as retinal defects 8 . In human neural progenitor cells (hNPCs), CLN6 redistributed to sites enriched in NS4B (Extended Data Fig. 3d ). AP-LC-MS/MS experiments using CLN6 as bait identified common binding partners between NS4B and CLN6 (Extended Data Fig. 3e ). Furthermore, CLN6 associated specifically with mTOR and TELO2, important regulators of signalling pathways that are disrupted by ZIKV 7, 13 . Taken together, the ZIKV interactome revealed a number of new Flavivirus host-binding partners, including cellular proteins and signalling pathway components involved in neuronal development.
In patients, during early stages of development, ZIKV predominantly infects NPCs, causing microcephaly and other neurodevelopmental injuries 14 . To gain insights into ZIKV-induced changes, we used a human induced pluripotent stem cell-derived neuronal differentiation model 15 . Analysis of the global proteomic changes that occurred during differentiation of hNPCs into neurons revealed significant upregulation of neuronal differentiation markers such as βIII-tubulin (TUBB3), microtubule-associated proteins 2 and 6 (MAP2 and MAP6), neuronal cell adhesion molecule 1 (NCAM1), doublecortin (DCX) and ELAVlike RNA binding protein 3 (ELAVL3) ( Table 2) . Notably, ectopic expression of ZIKV-NS4B during differentiation specifically downregulated the expression of a subset of proteins involved in neuronal differentiation (for example, MAP2, MAP6, DPYSL3, DPYSL5 and CNTN2) as well as proteins associated with neurological diseases (for example, DOK3 and SUMO2), suggesting disruption of specific developmental programs ( Table 4) . These experiments unveil the distinct effects of ZIKV and ZIKV-NS4B on the proteome of differentiating hNPCs, revealing specific targets that are differentially regulated during neurogenesis.
Post-translational modifications of proteins, especially phosphorylation, have crucial roles in controlling the complex reorganization of signal-transduction pathways upon virus infections 16, 17 . We therefore used LC-MS/MS-based time-resolved phosphoproteomics 18 to investigate cellular pathway deregulation in ZIKV-infected SK-N-BE2 cells. This analysis identified 14,222 unique phosphorylation sites (localization probability ≥ 0.75; Extended Data Fig. 7a-d ), 1,216 of which were modulated upon ZIKV infection ( Fig. 2d and Supplementary Table 5 ). Analysis of enriched biological functions showed that pathways involved in cellular assembly and organization, cell-cycle regulation, nervous system development and neurological diseases were significantly modulated by ZIKV infection (Extended Data Fig. 8a and Supplementary Table 6 ). Notably, this approach allowed us to map specific phosphorylation events along entire cellular pathways, highlighting modulation of key processes such as ATM, AKT-mTOR and ERK-MAPK signalling cascades (Extended Data Figs. 7e, 8b and  Supplementary Tables 7, 8 ). We identified strong downregulation of the AKT-mTOR signalling pathway, as indicated by dephosphorylation of known AKT1 substrates (for example, DNMT1, TBC1D4 and LARP6), mTOR targets (for example, ANKRD17, LARP1, PATL1 and EEF2K), the central kinase S6K and its main effector protein S6. Consistently, we found increased phosphorylation of proteins, such as the negative regulator of autophagy DAP, at residues known to inhibit its suppressor function and consistent with the notion that autophagy is induced after ZIKV infection 7, 19 ( Fig. 2e and Extended Data Fig. 7f ). Notably, ZIKV infection additionally downregulated the MAPK-ERK-signalling pathway, since A-RAF and ERK2 as well as several substrates of the downstream ERK1/2 map kinases (EIF4EBP1, BAZ1B and TWIST) were significantly dephosphorylated upon ZIKV infection ( Tables 5, 8 ). These data enable us to quantitatively map individual phosphorylated residues onto signalling pathways on a global scale, identifying complex interactions between different cellular pathways (Extended Data Fig. 7e ). For instance, both ERK1/2 and mTOR pathways converge on S6K and modulate its phosphorylation status 20 ( Fig. 2e) , suggesting multiple possible mechanisms that could contribute to the observed ZIKV-induced upregulation of autophagy, decrease in hNPC proliferation and impairment of neurogenesis. Notably, upregulation of the ATM (ataxia-telangiectasia mutated)/ATR (ATM-and Rad3-related) DNA-damage pathway, as inferred from significantly increased phosphorylation of several substrates of ATR (NPM1, CGGBP and GINS2), DNAPK (XRCC4) and downstream effector proteins (H2AFX), as well as proteins involved in cell-cycle regulation and DNA-damage checkpoints (TOP2B, CDK1) E   NS1   NS4A   NS4B   NS5   prM   AIFM1   ATP2A2   BMS1   BOP1   BRIX1   C7orf50   CALM1   CAMK2G   CCDC137   CEBPZ   CMSS1   DDB1   DDX10   DDX18   DDX20   DDX21   DDX24   DDX3Y   DDX50   DICER1   DKC1   DNAJA1   DNAJA2   DNAJC9   EBNA1BP2   EIF2B3   ERAL1   EXOSC1   EXOSC10   EXOSC4   EXOSC9   FAU   FTSJ3   GEMIN4   GNB2L1   GNL2   GNL3   GPRASP1   GRWD1   GTF3C2   GTPBP4   H1FX   HACD3   HADHA  HADHB   HDLBP   HP1BP3   ICT1   IPO7   IPO9   KIAA0020   KPNB1   KRI1   KRR1   LARP1   LARP7   LLPH   LYAR   MAGED1   F5H0B0   MRTO4   MSH6   MTDH   MYBBP1A   NAP1L1   NAP1L1   NAP1L4   NAT10   NCL   NIFK   NOL10   NOP56   NUP107   NUP133   NUP160   NUP205   NUP43   NUP85   NUP98   PDE2A   PEX19   POP1   PPAN   PPM1G   PRKDC   PRSS12   PTCD3   RBM28   RBM34   RCN2   RFC1   RPLP0   RPLP1  RPLP2   RPN1   RPSA   RRP12   RSL1D1   SDAD1   SERBP1   SET   SMC2  SMC4   SQSTM1   SRPK1   SRRT   SRSF5   SURF6   TARBP2   TMCO1   TOP1   TRIM26  TUBB3  USP9X   VPS16   XPOT   ZC3HAV1   ZCCHC8   ZFR   ZNF512   ZNF622   ZNF629   B2RD90  B4DLN1   Q59GX9   CEP250   CEP63   CHD8   NOA1   PARP2  PDAP1   SEP15   DMD   EI24   SCD   AGPAT6   FADS2  ICMT   LBR  PHB  SEC61B   SPTLC1  SSR3   STT3A   SURF4   TIMM23   ESYT1   AAAS   AAR2   ABCB6   ALG8   ATP1A1   ATP1A3   ATP1B1   ATP2A1   ATP2B1   AUP1   CCDC47   CDIPT   CDS2  CHPT1   CKAP4   COPG2   COX15   DDOST   DERL2   DHCR24   DNAJC13   EBP   ELOVL1  ERLIN1   ERLIN2   FAM134C   FXYD6   GNAI1   H2AFY   HAX1   HLA-A   HM13   HSD17B12   IMMT   IPO4   KRTCAP2   LPCAT1   LPGAT1   LPHN2   MLLT11   MPDU1 MT-CO2 Letter reSeArCH could be observed (Supplementary Tables 5, 8 ). This analysis highlights previously unreported ZIKV targets with known functions in neurogenesis. Among these targets, we note dephosphorylation of proteins, such as p38 MAPK, MARCKS (one of the main PKC substrates) and DPYSL2, activation of which positively modulates neurite outgrowth and brain development [21] [22] [23] ( Fig. 2e and Extended Data Fig. 8e ). To assess the functional relevance of the newly identified host factors, we selected cellular targets regulated either at the proteome (n = 26), phosphoproteome (n = 8) or interactome (n = 21) level by ZIKV, and evaluated the consequences of virus infection on gene silencing (Fig. 3a , Extended Data Fig. 9a-c and Supplementary Table 9 ). This approach identified 17 host factors for which silencing significantly reduced ZIKV replication compared to non-targeting controls (Fig. 3a) . In addition to confirming the essential role for recently described cellular factors in ZIKV replication, such as STT3A, MGGT1 and MSI1 [24] [25] [26] , we identified 14 additional host proteins that are required for ZIKV replication. Among these were proteins, the cellular abundance of which was strongly decreased upon NS4B expression and/or ZIKV infection in differentiating hNPCs (DOK3, XIRP2, YIPF4 and LMOD3), proteins that changed phosphorylation status upon ZIKV infection (LMO7, FXR1 and LARP7) and ZIKV-interacting proteins (LARP7 and LYAR, interacting with capsid, and BSG and CLN6, interacting Letter reSeArCH with NS4B) (Fig. 3a) . Validation experiments confirmed that knockdown of CEND1, CLN6, CHP1, LMOD3, TMEM41b or BSG resulted in inhibition of ZIKV replication ( Fig. 3b and Extended Data Fig. 9d, e) . Moreover, infection of hNPCs with two different ZIKV isolates (H/PF/2013 and MR766) recruited CLN6 and TMEM41b to sites that were enriched in double-stranded (ds)RNA and NS4B ( Fig. 3c-e) .
We combined quantitative information at the proteome, phosphoproteome and interactome levels with publicly available interaction databases in order to obtain a holistic perspective on the effect of ZIKV on neuronal cells (Extended Data Fig. 10 and Supplementary Table 10 ). This orthogonal intersection can be used to infer hotspots that are targeted by ZIKV at multiple levels. For example, LARP7, which interacts specifically with capsid, is additionally hypophosphorylated, whereas LMO7 is simultaneously downregulated at the protein level and hyperphosphorylated upon ZIKV infection (Fig. 3f ).
Our data provide valuable insights into how ZIKV exerts its action on candidate proteins that have previously been identified in genetic or drug-based screens. Among the recently identified ZIKV inhibitors 27 is digoxin, an inhibitor of the ATP1A1 Na + /K + ATPase, which is identified here to interact specifically with NS4B. Fingolimod inhibits the sphingosine-1-phosphate receptor, which is persistently hypophosphorylated upon ZIKV infection. Mycophenolic acid impairs inosine-5-monophosphate dehydrogenase 1; the cellular abundance of this protein is markedly downregulated in ZIKVinfected cells. Although some of the ZIKV-binding partners that have been identified here may associate with orthologues of closely related flaviviruses (for example, dengue virus and West Nile virus), their role in ZIKV-related pathogenesis might in addition rely on the unique ability of ZIKV to cross the placental barrier and reach the developing brain 28 . +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  +  C  C  C  C  C  C  C  C  4B  4B  4B  4B  4B  4B 4B  4B  4B  4B  4B  4B  4B Virus titre (% of NT) 
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Our study suggests that ZIKV evolved multiple mechanisms to usurp, exploit or perturb fundamental cellular processes, ultimately contributing to the broad spectrum of pathological abnormalities observed in humans. In addition, this study provides a resource for streamlining ZIKV research efforts and considering or excluding intracellular pathways for specific therapeutic interventions.
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Data reporting.
No statistical methods were used to predetermine sample size. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Cell lines and reagents. HeLa S3 cells (CCL-2.2) and Vero E6 cells (CRL-1586) were purchased from ATCC. SK-N-BE2 cells were provided by R. Klein (MPI of Neurobiology, Munich). HEK293 cells were a gift from A. Bowie (Trinity College, Dublin). hNPCs were generated as described below. All cell lines were tested to be mycoplasma-free and their identity verified by STR profiling. Primary antibodies used in this study were: rabbit polyclonal anti-CEND1 (1:5,000 western blot; ab113076, Abcam), rabbit polyclonal anti-RBFOX2 (1:500 western blot; HPA006240, Sigma-Aldrich), rabbit polyclonal anti-CLN6 (1:500 western blot; SAB4502281, Sigma-Aldrich), rabbit polyclonal anti-CHP1 (1:500 western blot; PA5-29876, Thermo-Fisher), rabbit polyclonal anti-BSG (1:2,000 western blot; HPA036048, Sigma-Aldrich), rabbit polyclonal anti-TMEM41b (1:250 western blot; HPA014946, Sigma-Aldrich), mouse monoclonal anti-dsRNA J2 (1:400 immunofluorescence; Scicons), mouse IgG2bκ anti-haemagglutinin (HA) (1:500 immunoflorescence; 12CA5, Sigma-Aldrich), rabbit polyclonal anti-DENV-NS4B (dengue virus protein NS4B) (1:100 IFA; 1:500 western blot; GTX124250; Genetex; this antibody cross-reacts with ZIKV-NS4B, as validated by immunodetection of ZIKV-NS4B in cells transduced with HA-tagged NS4B or ZIKV-infected cell lysates (Extended Data Fig. 4b) ). For detection of NS4B and capsid upon ZIKV infection by western blotting, the rabbit polyclonal anti-ZIKV-NS4B (1:1,000 western blot; GTX133311; Genetex) and anti-ZIKV capsid (1:1,000 western blot; GTX133317, Genetex) were used. For detection of phosphorylated and total protein abundance by western blotting, mouse monoclonal anti-gammaH2Ax (ab22551, Abcam) and the following rabbit monoclonal antibodies were used (Cell Signaling Technology): anti-MARCKS (D88D11) and anti-phosphorylated MARCKS (D13E4), rabbit monoclonal anti-mTOR (7C10) and anti-phosphorylated mTOR (D9C2), p38-MAPK (D13E1) and anti-phosphorylated p38-MAPK (D3F9), S6 ribosomal protein (5G10) and anti-phosphorylated S6 (D57.2.2E). Where indicated, to increase the basal phosphorylation of certain cellular proteins, 12-O-tetradecanoylphorbol-13-acetate (TPA, Cell Signaling Technologies) or DMSO, were added to the culture medium (32 nM), 15 min before collection of the cell lysates for western blot analysis. For characterization of hNPCs by immunofluorescence, the following antibodies were used: mouse anti-GFAP (G3893, SigmaAldrich), rat anti-Ki-67 (14-5698, EBioscience), mouse anti-MAP2 (M4403, clone HM-2, Sigma-Aldrich), mouse anti-nestin (MAB5326, clone 10C2, Millipore) and rabbit anti-Sox2 (ab137385, Abcam). Generation, maintenance and differentiation of hNPCs. Human induced pluripotent stem cells (iPSCs) generated from healthy patient fibroblasts 29 were maintained in mTeSRTM 1 medium (STEMCELL Technologies) on Geltrex (ThermoFischer Scientific) plates in the absence of feeders. The iPSCs were regularly confirmed to be mycoplasma-negative. To generate hNPCs, iPSC colonies were collected with a cell scraper to ensure that relatively big colonies remained and these were cultured in suspension to form embryoid bodies in DMEM/F-12, 0.5% N2 supplement (Gibco), 5 μM dorsomorphin (Sigma-Aldrich), 10 μM SB431542 (Sigma-Aldrich) and 10 μM Rho-associated kinase inhibitor (ROCK; Y-27632, StemCell Technologies). Embryoid bodies were grown for five days and the medium was changed every other day before gentle trituration and attachment on poly-ornithine-laminin-coated dishes in NPC medium, which consisted of DMEM/F-12, 0.5% N2, 1% B27 supplement with 10 ng ml −1 bFGF (Peprotech 100-18B-50) and 10 μM ROCK inhibitor. Three to four days after plating the embryoid bodies, neural rosettes were manually isolated, dissociated mechanically to single cells and plated on fresh poly-ornithine-laminin-coated dishes in NPC medium with 10 μM ROCK inhibitor. On the next day, the medium was changed to NPC medium without ROCK and NPCs were propagated for up to 12 passages by splitting with accutase when 70-80% confluency was reached. For short-term differentiation experiments (Fig. 3c-e and Extended Data Fig. 4 ), 2 × 10 5 cells were seeded in six-well plates, transduced with empty lentiviruses (NT), lentiviruses expressing HCV-or ZIKV-NS4B or infected with an MOI of 0.01 of ZIKV H/PF/2013. After 48 h, differentiation was induced for five days by growth factor withdrawal and addition of 10 μM ROCK inhibitor, while undifferentiated cells were kept in NPC medium in the presence of bFGF. In both cases, the medium was replaced every other day. Cell pellets were collected, snap-frozen and processed for LC-MS/MS analysis as described below. Virus strains, virus stocks preparation and generation of lentiviruses. ZIKV strains H/PF/2013 and MR766 were obtained from the European Virus Archive (EVAg, France). Virus stocks were passaged once on VeroE6 cells and viruscontaining cell culture supernatants or conditioned medium from uninfected cells were collected from day 3 to 8 post-infection. Supernatants were filtered through a 0.45-μM pore-size filter and stored at −70 °C. Titres of infectious virus were determined by plaque assay as described below. For infection of hNPCs, virus stocks were diluted in hNPC medium and cells were inoculated for 2 h at 37 °C. Inocula were removed and fresh hNPC medium (basal or differentiation) was added. Mock cells were inoculated with equal amounts of conditioned medium.
For the generation of lentiviruses that expressed the individual HA-tagged ZIKV viral proteins or Flag-tagged host proteins, synthetic cDNAs (sequences based on recombinant ZIKV strain FSS13025, Asian lineage) were obtained in pUDC57 vectors and the fusion gene was inserted into the lentiviral pWPI expression plasmid. The lentivirus that expresses the HA-tagged HCV-NS4B of has previously been described 30 . Lentivirus stocks were produced and titrated following standard procedures. Nucleotide sequences of each construct are available from the corresponding authors upon request. Lentiviral shRNA library production and shRNA screen. From the MISSION TRC lentiviral library (Sigma-Aldrich), 54 MS hits and 4 controls were selected and shRNA were produced as follows. Two different shRNA-expressing lentiviruses per gene (116 shRNAs in total; Supplementary Table 10) were individually produced in HEK 293T cells (8 × 10 5 ) that were plated one day before transfection. Transfections were performed as previously described 4 using the packaging plasmids psPAX2 and pMD-VSV-G (provided by D. Trono) and shRNA-encoding pLKO-puro plasmids. Viruses were collected at 48 and 72 h post-transfection, clarified by centrifugation and pooled before freezing. Controls included the nontargeting shRNA-encoding plasmids SHC001 and SHC002 (NT1 and NT2) as well as the known virus restriction factors ATP6V0C and Musashi1. For quality-control purposes, approximately 25% of random samples were used to measure lentiviral titres. For screening purposes, 10,000 SK-N-BE2 cells per well were seeded in 96-well plates in 90 μl of complete DMEM and 24 h later cells were transduced with 30 μl of each lentivirus (MOI ≈ 3) in triplicate wells/replica and three independent biological replicates. Three days later, cells were infected with an MOI of 0.1 of ZIKV H/PF/2013. Subsequently, 48 h post-infection, cell supernatants were used for titration by PFU assay. Cell viability was measured by a resazurin-based cell-viability assay, on plates which were transduced with shRNAs in parallel but were not infected with ZIKV. In brief, 50 μg ml −1 resazurin was added to each well of a 96-well plate and incubated for 30 min at 37 °C, followed by measurement of fluorescence (535/590 nm) using an Infinite 200 PRO series microplate reader (Tecan). The normalization for the virus titres and fluorescence measurements were performed in two steps. First, the measurements in each replicate experiment were adjusted by the median factor of the replicate (the median of X g,i /median(X g,1 , X g,2 , X g,3 ) across all the shRNAs (g = 1,2,...,116), where X g,i is the titre of gth shRNA in ith replicate). Second, the adjusted measurements were normalized, such that the average signal of non-targeting controls was 100%. The following criteria were applied to select hits: ≥50% decrease in median viral titres with two shRNAs or ≥75% if only one shRNA was efficient; cell viability ≥75% of non-targeting controls. Validation experiments for selected shRNAs ( Fig. 3b and Extended Data Fig. 9d , e) were performed in 24-well plates using the same overall protocol. Virus titration by plaque assay. Confluent monolayers of VeroE6 cells were infected with serial tenfold dilutions of virus supernatants for 2 h at 37 °C. The inoculum was removed and replaced with serum-free MEM (Gibco, Life Technologies) containing 1.5% carboxymethylcellulose (Sigma-Aldrich). Four days post-infection, cells were fixed for 2 h at room temperature with formaldehyde directly added to the medium to a final concentration of 5%. Fixed cells were washed extensively with water before staining with H 2 O containing 1% crystal violet and 10% ethanol for 30 min. After rinsing with water, the number of plaques was counted and virus titres were calculated. Sample preparation for deep-proteomic and phosphoproteomic analyses. For proteomic and phosphoproteomic analysis, SK-N-BE2 cells (10 7 cells per biological replicate per condition; 4 biological replicates per condition), were mock-infected or infected with ZIKV H/PF/2013 at an MOI of 3. Cell pellets were collected after 24, 48 and 72 h, lysed in 1 ml of lysis buffer (10 mM TrisHCl (pH 7.5), 4% SDS and 0.05 mM DTT supplemented with complete protease and phosphatase inhibitor cocktails (Roche)), boiled 10 min at 98 °C, and sonicated (4 °C for 15 min, or until a homogeneous suspension was formed). Clarified protein lysates were precipitated with acetone, and normalized protein mixtures resuspended in 500 μl TFE digestion buffer. Protein digestion was performed by adding 1:100 (protein:enzyme) trypsin and LysC with rapid agitation (2,000 r.p.m.) overnight at 37 °C. An aliquot of the peptide mixtures was used for the determination of the total proteome (10%), while the remaining peptide mixture (90%) was processed for phosphopeptide enrichment using the EasyPhos protocol. For proteomic analysis of primary cells, hNPCs were seeded in six-well plates (2 × 10 5 cells per well) and either mock-infected, infected with an MOI of 0.01 of ZIKV or transduced with lentiviruses expressing HA-tagged ZIKV-NS4B or HCV-NS4B (MOI = 3). Two days after infection or lentivirus transduction, cells were left in hNPC proliferation medium or neuronal differentiation was initiated by culturing the cells in hNPC differentiation medium. Five days later, cell pellets were collected and processed for label-free LC-MS/MS analysis as described previously 31 . Each condition was performed in quadruplicate biological replicates.
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Deep-proteome and phosphoproteome LC-MS/MS analysis and data processing. Peptide mixtures were separated on a 50-cm reversed-phase column (diameter of 75 μm packed in-house with ReproSil-Pur C18-AQ 1.9 μm resin (Dr. Maisch GmbH)) as previously described 32 . Raw MS files were processed within the MaxQuant environment (version 1.5.7) using the integrated Andromeda search engine with false discovery rate (FDR) ≤ 0.01 at the protein, peptide and modification level. Proteome and phosphoproteome files were assigned to separate search parameter groups. The search included fixed modifications for carbamidomethyl (C) and variable modifications for oxidized methionine (M), acetylation (protein N-term), and phospho (STY) for phosphoproteome files. Peptides with at least six amino acids were considered for identification, and 'match between runs' was enabled with a matching time window of 0.7 min to transfer MS1 identifications between runs. Peptides and proteins were identified using a UniProt FASTA database from human (UniprotKB release 2015_08 including isoforms and unreviewed sequences) and ZIKV virus polyprotein corresponding to the H/PF/2013 strain (NCBI GenBank KJ776791.2; individual viral cleavage products were manually annotated). Sample preparation for affinity purification of ZIKV proteins and cellular proteins. For the determination of the ZIKV interactome, four independent affinity purifications were performed for each ZIKV HA-tagged viral protein. SK-N-BE2 cells were transduced with an MOI of 3 of each lentivirus (8 × 10 6 cells per dish) and 72 h later cells were scraped into 1 ml of lysis buffer (50 mM Tris (pH 8), 150 mM NaCl, 0.5% NP-40, cOmplete protease inhibitor cocktail, Roche) and HA-affinity purifications were performed as described previously 33 . In brief, clarified cell lysates were incubated with anti-HA-specific beads for 3 h at 4 °C, and non-specifically bound proteins removed by three washes with lysis buffer and five washes with washing buffer (50 mM Tris (pH 8), 150 mM NaCl). Bound proteins were denatured by incubation in 20 μl guanidinium chloride buffer (600 mM GdmCl, 1 mM TCEP, 4 mM CAA, 100 mM Tris-HCl (pH 8)). After digestion with 1 μg LysC (WAKO Chemicals USA) at room temperature for 3 h, the suspension was diluted in 100 mM Tris-HCl (pH 8), and the protein solution was digested with trypsin (Promega) overnight at room temperature. Peptides were purified on stage tips with three C18 Empore filter discs (3M) and analysed by mass spectrometry as previously described 34 . For the analysis of CLN6 and other host-factor interactomes, SK-N-BE2 cells were transduced with the corresponding Flag-tagged lentiviruses and 72 h later cell lysates were processed as described above, using agarose anti-Flag M2 beads (Sigma-Aldrich). Data processing of AP-LC-MS/MS samples. Raw mass-spectrometry data were processed with MaxQuant (software version 1.5.3) using the built-in Andromeda search engine to search against the human proteome (UniprotKB release 2015_08 including isoforms and unreviewed sequences) plus ZIKV virus polyprotein (ZIKV strain FSS13025, Asian lineage; NCBI GenBank KU955593.1 with individual viral cleavage products manually annotated), Gaussia luciferase (Q9BLZ2), HCV-NS4B (E7ELX2) sequences, and the label-free quantification algorithm as described previously 35 . In MaxQuant, carbamidomethylation was set as fixed and methionine oxidation and N-terminal acetylation as variable modifications, using an initial mass tolerance of 6 p.p.m. for the precursor ion and 0.5 Da for the fragment ions. Search results were filtered with a FDR of 0.01 for peptide and protein identifications. Statistical analysis of MS data. MaxQuant output files (proteinGroups.txt and 'Phospho (STY) Sites.txt' for proteome and phosphoproteome data, respectively) were processed by a combination of in-house R (version 3.3), Julia (version 0.5) and Stan (version 2.14) scripts.
To account for the variation in the analysed biological sample amounts and MS performance, we inferred the normalizing multipliers for each MS run so that the normalized LFQ values of the representative set of proteins (around 500 randomly values were selected from the ones quantified in most of the normalized samples) do not change between the samples. First, this procedure was applied to normalize replicate MS runs within each condition, and then the normalization multipliers were further adjusted to normalize the conditions between each other. For the analysis of proteome changes the LFQ intensities were fit to a Bayesian generalized linear model (GLM) for each protein group (raw intensities of each phosphosite for phosphoproteome data) individually. The model used horseshoe priors for the treatment effects, and the natural logarithm as a linking function for protein intensities. Additional parameters with horseshoe priors were introduced to model the biological variation within replicate samples. The MS measurements were set to follow the Laplace distribution. Technical MS runs from both LTQ-Orbitrap XL and Orbitrap Q Exactive HF were used to estimate the signal-to-noise ratio and sensitivity of protein quantification across the whole dynamic range of protein intensities. We used the obtained technical variation models to define the scale parameter of the Laplace distribution for each individual MS measurement as well as scale and location parameters of the logistic distribution for missing MS measurements. To analyse the hNPC proteome, we used the following GLM (in R GLM formula notation): log(intensity) when host proteins were used as baits. The posterior distributions of model parameters were inferred using the Hamiltonian Markov chain Monte Carlo (MCMC) method (Stan version 2.14), using eight parallel MCMC chains, 2,000 warmup and 2,000 sampling iterations taking every fourth sample from each chain. The statistical significance of a hypothesis that given model variable x is positive given data Y (one-sided P value), that is, the probability that a random sample from the posterior distribution of x would be non-positive (P(x ≤ 0|Y)), was calculated by approximating the posterior distribution from the MCMC samples using Gaussian kernel with Silverman's ruleof-thumb bandwidth. For the ≠ x 0 hypothesis, the two-sided P value was defined as min(P(x ≤ 0|Y), P(x ≥ 0|Y)). The following criteria were used for reporting significantly regulated proteins and phosphosites: P≤ 0.01 and |median (log 2 (fold change))| ≥ 1 (Supplementary Tables 2, 5, 9 ).
To filter for specific interactions, the inferred posterior distributions of protein intensities in each viral bait of the ZIKV AP-LC-MS/MS dataset were compared with the average distribution of the same protein in all other baits excluding capsid protein (owing to its highly hydrophobic character and multiple subcellular localizations). The interaction was considered specific, if the one-sided P value (P(x bait ≤ x background |Y), where x bait is the protein intensity in the pull-downs of a given bait, and x background is its intensity in the pull-down experiments of the other baits) was below 5 × 10 −5 for capsid bait (since there were no other baits with the same biochemical properties) and 5 × 10 −2 for the other baits, and median protein enrichment against the background was more than 5.56-fold (= 2 2.5 ) for high-confidence and twofold for the lower-confidence set of ZIKV protein interactions. The same filtering strategy was applied to AP-LC-MS/MS experiments of selected host targets; the P-value cutoff was 0.02 and log 2 (fold change) ≥ 1.5. For the representation of networks, subcellular localization of cellular proteins was extracted from Gene Ontology (version 2016-Sep-21).
Merging of datasets.
The integration of all AP-LC-MS/MS, proteomic and phosphoproteomic data was done by matching protein groups of individual datasets to each other using in-house scripts. The protein groups were matched if they shared a common protein accession code ('Majority Protein ACs' column in MaxQuant output). In ambiguous situations (for example, one protein group of dataset A shares different protein sequences with several protein groups of dataset B), the priority was given to the reviewed protein sequences and canonical isoforms. Integrating published protein-protein interactions, kinase-substrate relations and regulatory sites data. For overlaying our data with published protein-protein interactions, we used the IntAct interactions database (version 2017.04.08), IntAct complexes collection (version 2017.04.08) and CORUM protein complexes database (version 2017.03.15). The interaction (physical association) was included if both interacting partners were significantly enriched in the same ZIKV bait. For published AP-MS interactions, we additionally required that one of the interacting partners was a bait. To integrate AP-LC-MS/MS datasets with proteomic and phosphoproteomic screens, only published direct interactions (including kinasesubstrate relationships) were considered.
For phosphoproteomic analysis kinase-substrate relations and regulatory sites were extracted from PhosphositePlus 36 (kinase_substrate_dataset from 21 March 2017 and regulatory_sites from 18 April 2017, respectively). Ingenuity pathway analysis. Proteome and phosphoproteome changes along with unchanged proteins or sites, respectively, were submitted to the core ingenuity pathway analysis (IPA). The following cut-offs were set for differentially expressed proteins: P ≤ 0.01 and |log 2 (fold change)| ≥ 1.5. Ingenuity knowledge base was used as a reference dataset, while only experimentally observed findings were used for confidence filtering. No filters were applied at the level of species, tissues or cell lines. Input datasets were used for the functional analysis to identify biological functions and canonical pathways that were most significant. Righttailed Fisher's exact tests were used to calculate P values. Biological functions or pathways were considered significant when unadjusted P ≤ 0.05. Corresponding Benjamini-Hochberg-adjusted P values were calculated and are presented in the Supplementary Tables. Co-immunoprecipitation assays. For validation of ZIKV-NS4B interacting proteins, SK-N-BE2 cells were seeded into 15-cm 2 dishes (8 × 10 6 cells per dish), transduced with lentiviruses expressing ZIKV, DENV or HCV HA-tagged viral proteins or conditioned cell-culture medium. After 72 h of transduction, cell monolayers were scraped into 1 ml lysis buffer (50 mM Tris-HCl (pH 8.0), 0.5% NP-40, 150 mM NaCl and protease inhibitor cocktail (cOmplete, Roche)), and clarified lysates were processed for immunoprecipitation as previously described 33 . Eluted proteins were further analysed by western blot as specified in the figure
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Extended Data Fig. 1 | Design rationale, expression and subcellular  localization of HA-tagged ZIKV proteins. a, Schematic representation of ZIKV HA-tagged viral proteins and controls used in this study and experimental set-up used to generate the ZIKV cellular interactome. The full-length ZIKV genome is shown at the top, with the 5′ and 3′ untranslated regions depicted with their putative secondary structures. Polyprotein cleavage products are separated by vertical lines and labelled as specified. The individual open reading frames (ORFs) of each of the ZIKV proteins were fused with an HA epitope either at their N terminus or C terminus as depicted. Numbers above each sequence refer to the nucleotide sequence of the ZIKV isolate FSS13025 used as reference (GeneBank: KU955593.1). To ensure the correct subcellular localization and protein topology, the sequence of the capsid anchor (C anch ), the transmembrane domain of prM (prM TM ) and the transmembrane domain of Envelope (E TM ) were fused at the N termini of prM, envelope and NS1, respectively. Additionally, given the complex topology of NS2A, the transmembrane domain of envelope, and a fusion protein encoding the first and the last 50 amino acids of NS1 was fused at its N terminus. As additional controls, an empty pWPI-lentiviral vector (NT) or HA-tagged non-structural protein 4B of hepatitis C virus (NS4B-HCV) and Gaussia luciferase (G. luciferase) were included to monitor for non-specific binding to the anti-HA beads as well as organelle-dependent enrichment artefacts in AP-LC-MS/MS analysis. b, Intracellular levels of ZIKV proteins in lentivirus-transduced SK-N-BE2 cells. SK-N-BE2 cells were transduced with lentiviruses encoding each of the ZIKV proteins at an MOI of 3, and 72 h later cell lysates that had been clarified by centrifugation were used for western blotting against HA and β-actin. Numbers on the left refer to molecular weight standards given in kDa. Asterisks mark proteins expressed at a lower level, which can be observed upon longer exposure of the membrane. Note that C-terminally tagged NS2A and N-terminally tagged NS2B-3 could not be detected, whereas the C-terminally tagged NS2B-3 fusion protein was expressed at the expected molecular weight, and was therefore used for further experiments in this study. The bottom lane indicates the predicted molecular weight of each viral protein in kDa. n = 2 independent experiments. A representative blot is shown. c, Subcellular localization of ZIKV proteins in lentivirustransduced SK-N-BE2 cells. SK-N-BE2 cells were seeded in 24-well plates and transduced as described above. After 72 h of transduction, viral proteins were detected using rabbit anti-HA antibody and Alexa-Fluor488-conjugated secondary antibody and imaged by confocal microscopy. Scale bar, 10 μm. n = 1 experiment. Fig. 7 | Time-resolved phosphoproteomic analysis of  ZIKV-infected SK-N-BE2 cells. a, Total number of phosphopeptides, phosphosites and phosphoproteins identified in this study. b, Total number of phosphosites identified across biological replicates and conditions (n = 4). c, Relative percentage of class I, II and III phosphosites (localization probability >0.75) and phosphorylation of specific Ser, Thr and Tyr residues. d, Venn diagram of significantly changing phosphosites at 24, 48 and 72 h post-infection (h.p.i.). e, Network analysis of cellular processes significantly modulated by ZIKV infection at phosphorylation level (IPA). Nodes are canonical pathways identified with Fisher's exact test; edges are shared proteins between the pathways (n = 4 independent experiments, right-tailed Fisher's exact test, Benjamini-Hochbergadjusted P ≤ 0.05). f, Profile plots of significantly changing phosphosites, mapped to pathways in Fig. 3d , and their corresponding total protein levels at 24, 48 and 72 h after ZIKV infection (orange for phosphorylation levels, yellow for protein levels) or mock treatment (grey). Numbers next to protein names refer to MaxQuant protein group IDs (Supplementary  Table 5 ). Points are normalized intensities of individual replicates, solid line is median, filled area corresponds to 25-75 percentiles, dashed lines mark 2.5-97.5 percentiles of the posterior distribution. n = 4 independent experiments; Bayesian statistical modelling.
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Extended Data Fig. 9 | Effect of shRNA-mediated silencing of  ZIKV-modulated host proteins on viral replication. a, Schematic representation of the experimental set-up used for the shRNA screen. Selected target genes were chosen among the cellular host factors specifically binding ZIKV-capsid or -NS4B (interactome; n = 26), significantly regulated at the phosphoproteomic level by ZIKV infection (phosphoproteome; n = 6) or significantly regulated at the proteomic level both by ZIKV infection and ZIKV-NS4B-expression in hNPCs (proteome; n = 23). Controls included non-targeting shRNA of two different pLKO-based lentivirus generations (NT1 and NT2) used as reference; and shRNAs targeting ATP6V0C and Musashi-1, which impair flavivirus pH-dependent viral entry and ZIKV replication, respectively. Two individual shRNAs per gene were selected from the MISSION TRC library (Sigma-Aldrich), and used for lentivirus production in HEK293T cells as described in the Methods. SK-N-BE2 cells were transduced with individual lentiviruses (three wells per shRNA) in three independent experiments. Three days post-transduction, cells were infected with ZIKV H/PF/2013 (MOI = 0.1) and 48 h later virus-containing supernatants were used for titration by PFU assay. The cellular viability was assessed with a resazurin-based assay that was performed in parallel. b, c, ZIKV titres and cell viability upon knockdown of selected host factors. Viral titres, as determined by PFU assay, and cell viability, as determined by resazurin assay, are expressed as a percentage of the non-targeting controls. n = 3 independent experiments. The box plot middle line corresponds to the median, the hinges represent the first and third quartiles, the lower (upper) whisker extends from the lower (upper) hinge to the minimum (maximum) value no further than 1.5× the interquartile range. d, Cell viability of SK-N-BE2 cells upon knockdown of selected host factors (n = 4 independent experiments, normalized mean ± s.d.; related to Fig. 3b) . e, Validation of the silencing efficiency of selected shRNA targeting ZIKV host factors. Gene silencing was evaluated for each cellular protein via western blot detection using the antibodies specified on the right. Asterisk indicates non-specific bands, numbers on the left indicate molecular weight markers expressed in kDa. n = 2 independent experiments. Representative blots are shown. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
The analysis scripts used for analysis of proteomic data were written in R (version 3.3), Julia (version 0.5) and Stan (version 2.14) and are available from the corresponding author upon request. For processing and analysis of immunofluorescent images, FiJi (version 1.50i) was used.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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